医学
美罗华
胃肠病学
内科学
血管炎
硫唑嘌呤
随机对照试验
冷球蛋白血症
环磷酰胺
血浆置换术
耐火材料(行星科学)
外科
免疫学
化疗
丙型肝炎病毒
淋巴瘤
抗体
病毒
疾病
物理
天体生物学
作者
Salvatore De Vita,Luca Quartuccio,Miriam Isola,Cesare Mazzaro,Patrizia Scaini,Marco Lenzi,M. Campanini,Caterina Naclerio,Antonio Tavoni,Maurizio Pietrogrande,Clodoveo Ferri,Maria Teresa Mascia,Paola Masolini,Alen Zabotti,M. Maset,Dario Roccatello,Anna Linda Zignego,Pietro Pioltelli,Armando Gabrielli,Davide Filippini
摘要
Abstract Objective To conduct a long‐term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). Methods Fifty‐nine patients with CV and related skin ulcers, active glomerulonephritis, or refractory peripheral neuropathy were enrolled. In CV patients who also had hepatitis C virus (HCV) infection, treatment of the HCV infection with antiviral agents had previously failed or was not indicated. Patients were randomized to the non‐RTX group (to receive conventional treatment, consisting of 1 of the following 3: glucocorticoids; azathioprine or cyclophosphamide; or plasmapheresis) or the RTX group (to receive 2 infusions of 1 gm each, with a lowering of the glucocorticoid dosage when possible, and with a second course of RTX at relapse). Patients in the non‐RTX group who did not respond to treatment could be switched to the RTX group. Study duration was 24 months. Results Survival of treatment at 12 months (i.e., the proportion of patients who continued taking their initial therapy), the primary end point, was statistically higher in the RTX group (64.3% versus 3.5% [ P < 0.0001]), as well as at 3 months (92.9% versus 13.8% [ P < 0.0001]), 6 months (71.4% versus 3.5% [ P < 0.0001]), and 24 months (60.7% versus 3.5% [ P < 0.0001]). The Birmingham Vasculitis Activity Score decreased only after treatment with RTX (from a mean ± SD of 11.9 ± 5.4 at baseline to 7.1 ± 5.7 at month 2; P < 0.001) up to month 24 (4.4 ± 4.6; P < 0.0001). RTX appeared to be superior therapy for all 3 target organ manifestations, and it was as effective as conventional therapy. The median duration of response to RTX was 18 months. Overall, RTX treatment was well tolerated. Conclusion RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI